AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21541781
Drug: Macitentan 300
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan 300 mg
Trial: 17400413
Drug: computer-based hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: computer-based hormone therapy decision-aid
Trial: 10419902
Drug: Functional drug
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional drug efflux (assessed using Di(OC)(2) and Rhodamine 123)
Trial: 7587453
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training consisting of 1 h of group walking twice daily, with intensity stratified into four levels based on initial exercise capacity.
Trial: 2276014
Drug: Adjuvant postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant postoperative combination chemotherapy (5‐fluorouracil, lomustine (CCNU) and vincristine)
Trial: 2276014
Drug: Adjuvant postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant postoperative combination chemotherapy
Trial: 6157615
Drug: Synchronization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronization therapy (control group)
Trial: 6157615
Drug: Synchronization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronization therapy (for advanced non-Hodgkin lymphomas)
Trial: 31641913
Drug: QL2 regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL2 regional anesthesia with 150 mg of ropivacaine combined with standard analgesia
Trial: 21719865
Drug: Injectable poly-L-lactic
RxNorm normalized name: L-Lactic acid
DrugBank: L-Lactic acid (DB14475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable poly-L-lactic acid (PLLA)
Trial: 31469923
Drug: Injectable poly-D,L-lactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable poly-D,L-lactic acid (PDLLA)
Trial: 27403887
Drug: EMLA® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA® cream (anaesthetic cream), n = 34, applied on the volar part of the forearm, treatment repeated at increasing intervals over 8 weeks.
Trial: 27403887
Drug: Placebo cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream, n = 36, applied on the volar part of the forearm, treatment repeated at increasing intervals over 8 weeks.
Trial: 25271011
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 3 (250,000 IU, single dose in November)
Trial: 17202008
Drug: Lidocaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (2 mL, 40 mg, 2%)
Trial: 17202008
Drug: Diphenhydramine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (2 mL, 20 mg)
Trial: 17202008
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL normal saline)
Trial: 1480917
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg nightly (increased to 40 mg if cholesterol > 200 mg/dl after 6 weeks)
Trial: 1480917
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg twice daily (dose kept constant)
Trial: 6500445
Drug: Split tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split tetanus vaccine
Trial: 6500445
Drug: Normal adsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal adsorbed toxoid vaccine
Trial: 2944434
Drug: Ketanserin by
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin by continuous infusion
Trial: 2944434
Drug: Placebo (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equal infusion rate)
Trial: 27020698
Drug: Gel of
RxNorm normalized name: ZINC OXIDE 160 mg in 1 g TOPICAL OINTMENT [Angel of mine Diaper Rash]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel of chamomile
Trial: 27020698
Drug: Cream of
RxNorm normalized name: Nubasics Soup Cream of Chicken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream of urea
Trial: 23201763
Drug: Beta-alanine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (4 weeks loading phase of 4.8 g/day and 3.2 g/day thereafter)
Trial: 15998756
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein intake; specific dosage and duration not mentioned.
Trial: 12757058
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (50 mg initially, increased to 100 mg or decreased to 25 mg depending on efficacy and/or tolerability)
Trial: 1478168
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg twice daily for one year)
Trial: 24768247
Drug: Dose-reduction-by-half group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-reduction-by-half group
Trial: 24768247
Drug: Dose maintenance
RxNorm normalized name: XCOPRI 250mg Daily Dose Maintenance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose maintenance group
Trial: 20819899
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (0.5 mg/kg per day)
Trial: 20819899
Drug: Other glucocorticoid
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other glucocorticoid doses and preparations
Trial: 11081531
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg prednisolone daily for 2 weeks
Trial: 9002329
Drug: Tetravalent rhesus‐human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent rhesus‐human reassortant rotavirus vaccine (4 x 10(4) plaque‐forming units/dose)
Trial: 7039017
Drug: High oral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oral doses of prednisone
Trial: 22337714
Drug: FCR (fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCR (fludarabine and cyclophosphamide in combination with rituximab)
Trial: 22337714
Drug: FCCam (fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCCam (fludarabine and cyclophosphamide in combination with alemtuzumab)
Trial: 18503008
Drug: Standardized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized oral mixed meal
Trial: 18503008
Drug: Intraperitoneal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal glucose infusion
Trial: 15816811
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment at a dosage of 1.6 IU/day (0.53 mg/day) for 6 months followed by 12 months of active GH treatment
Trial: 15816811
Drug: Post-treatment follow-up
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment follow-up after cessation of GH treatment
Trial: 227618
Drug: 4-month exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month exercise program (3-4 weekly sessions)
Trial: 27521821
Drug: Pycnogenol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (50 mg orally, 3 times daily)
Trial: 27521821
Drug: Diosmin/Hesperidin (450/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmin/Hesperidin (450/50 mg orally, twice daily)
Trial: 23296063
Drug: Paclitaxel/platinum chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel/platinum chemotherapy followed by liposomal doxorubicin and gemcitabine (Group B)
Trial: 23296063
Drug: Paclitaxel/platinum chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel/platinum chemotherapy followed by platinum compounds, docetaxel and oral etoposide (Group A)
Trial: 23296063
Drug: Post-relapse treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-relapse treatment in Group B
Trial: 23296063
Drug: Post-relapse treatment
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-relapse treatment in Group A
Trial: 21970950
Drug: Bevacizumab (PRN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (PRN dosing regimen)
Trial: 21970950
Drug: Bevacizumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (monthly treatment)
Trial: 21970950
Drug: Ranibizumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (monthly treatment)
Trial: 18328464
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBTgsh)
Trial: 18328464
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBTgsh) and Behavioral weight loss (BWLgsh)
Trial: 16864762
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT), 10-session, manualized, individually administered regimen added to psychiatric consultation intervention
Trial: 12638392
Drug: Cetrorelix (CET)
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix (CET) single doses (0.25, 0.5, or 1 mg) on cycle day 3
Trial: 12638392
Drug: Cetrorelix (CET)
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix (CET) multiple doses from cycle day 3 to day 16
Trial: 9060527
Drug: Fluorouracil (FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (FU) and racemic leucovorin (d,l‐LV)
Trial: 9060527
Drug: Fluorouracil (FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (FU) combined with the pure l-isomer of leucovorin (l‐LV)
Trial: 8181576
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of low-dose recombinant interleukin-2 via central venous access (CVA)
Trial: 8181576
Drug: Systemic antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibiotics via the CVA
Trial: 8181576
Drug: Constant infusion
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant infusion of low dose streptokinase via the CVA
Trial: 2535983
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (1500 aPTT-U/24 h)
Trial: 2535983
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (3 x 5000 IU/24 h)
Trial: 9194109
Drug: Bio-Hep-B (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-Hep-B (2.5 micrograms/dose)
Trial: 9194109
Drug: Engerix-B (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B (10 micrograms/dose)
Trial: 3912647
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of arginine pyroglutamate three times a day
Trial: 30535959
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate tablet (test product)
Trial: 30535959
Drug: ZYTIGA® (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZYTIGA® (250 mg, reference product)
Trial: 21059213
Drug: MPH1 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPH1 (7.5 mg Isoleucine‐Proline‐Proline)
Trial: 21059213
Drug: MPH2 (6.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPH2 (6.6 mg Methionine‐Alanine‐Proline, 2.3 mg Leucine‐Proline‐Proline, 1.8 mg IPP)
Trial: 15857459
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel applied twice daily for 4 weeks
Trial: 7740405
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy for high-grade soft-tissue sarcomas
Trial: 7740405
Drug: Neoadjuvant induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant induction chemotherapy, regional perfusion with cytostatics (± hyperthermia), externally applicated deep regional tumor hyperthermia with systemic chemotherapy
Trial: 7740405
Drug: Uncontrolled adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncontrolled adjuvant treatment of soft-tissue sarcomas with cytostatic drugs
Trial: 2179591
Drug: Abdominal injection
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal injection of insulin for 3 days
Trial: 2179591
Drug: Rotating injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotating injection among arms, abdomen, and thighs for 3 days
Trial: 6102456
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg d-amphetamine administered intravenously
Trial: 27821644
Drug: Lesinurad 200
RxNorm normalized name: lesinurad 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 200 mg + allopurinol
Trial: 27821644
Drug: Lesinurad 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 400 mg + allopurinol
Trial: 21174586
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C and 400 IU natural vitamin E (RRR α tocopherol) daily from the second trimester until delivery
Trial: 11578890
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg with 4% lidocaine (Group I; n = 15)
Trial: 11578890
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL with saline (Group 2; n = 16)
Trial: 25277645
Drug: Amoxicillin/clavulanate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate and metronidazole (2-antimicrobial group)
Trial: 25277645
Drug: Amoxicillin/clavulanate (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (control group)
Trial: 25277645
Drug: Both antibiotics
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both antibiotics continued (2-antimicrobial group)
Trial: 20061435
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (50 mg/d)
Trial: 9641566
Drug: Local nasal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local nasal immunotherapy (LNIT)
Trial: 10812221
Drug: Priorix (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priorix (new MMR vaccine)
Trial: 10812221
Drug: Triviraten (widely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triviraten (widely used MMR vaccine)
Trial: 30948273
Drug: Niraparib 300
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 300 mg once daily continuously
Trial: 30241559
Drug: Pre-prepared PHEA
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-prepared PHEA equipment and drugs
Trial: 24481640
Drug: i-CEOP (intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-CEOP (intensive chemotherapy): cyclophosphamide 1,500 mg, epirubicin 150 mg, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5
Trial: 24481640
Drug: i-CEOP (intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-CEOP (intensive chemotherapy)
Trial: 24481640
Drug: s-CEOP (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s-CEOP (standard chemotherapy): cyclophosphamide 750 mg, epirubicin 75 mg, vincristine 1.4 mg/m2, prednisolone 100 mg days 1-5
Trial: 24481640
Drug: s-CEOP (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s-CEOP (standard chemotherapy)
Trial: 22205319
Drug: Moderately high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy)
Trial: 22205319
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (0.9 g/d, 0.3% of daily energy)
Trial: 22205319
Drug: Moderately high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy) among women with BMI ≥25
Trial: 22205319
Drug: Moderately high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately high in rTFAs (3.7 g/d, 1.5% of daily energy) among women with BMI <25
Trial: 17726919
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)
Trial: 12197367
Drug: CEE-MPA (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE-MPA (conjugated equine oestrogens 0.625 mg + medroxyprogesterone acetate 5 mg)
Trial: 7781462
Drug: 200 mg/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg/hr L-arginine
Trial: 7781462
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg erythromycin
Trial: 2180492
Drug: Chlorambucil at
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil at a daily dose of 0.1 mg/kg
Trial: 2180492
Drug: Stage A
RxNorm normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage A patients with hemoglobin ≥ 120 g/L and lymphocyte count < 30 x 10(9)/L
Trial: 31200160
Drug: Real indoor
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real indoor air purification (PM2.5 exposure reduced to 28.3 μg/m3)
Trial: 31200160
Drug: Sham indoor
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham indoor air purification (PM2.5 exposure at 56.9 μg/m3)
Trial: 21509668
Drug: Hongyou Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hongyou Ointment and Shengji Powder (CM group)
Trial: 21509668
Drug: Mupirocin ointment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin ointment, growth factor (bFGF), and Vaseline gauze (WM group)
Trial: 21509668
Drug: CM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM treatment
Trial: 11112243
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg (two 500-mg Extra Strength Tylenol tablets)
Trial: 9167744
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (AT II) infusion
Trial: 9167744
Drug: Baseline (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (without AT II infusion)
Trial: 8460050
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg p.o. HS on postoperative days 1, 2, and 3
Trial: 3079935
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day leuprolide acetate
Trial: 3079935
Drug: 3 mg/day
RxNorm normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/day diethylstilbestrol (DES)
Trial: 28695457
Drug: Islet cell
RxNorm normalized name: Islet cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islet cell antibody testing
Trial: 18685503
Drug: Symbiotic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic formulation (Flortec)
Trial: 18685503
Drug: Symbiotic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic formulation (Flortec) in IBS-predominant diarrhea
Trial: 16549835
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/d for 6 weeks, then 10 mg/d for 18 weeks
Trial: 8204703
Drug: UDCA 10
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 10 mg/kg/day for one year
Trial: 3301452
Drug: Long-acting propranolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting propranolol, 160 mg once daily
Trial: 3301452
Drug: Conventional propranolol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional propranolol, 40 mg three times daily
Trial: 29941495
Drug: Cholecalciferol (D3)
RxNorm normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (D3) 4,000 IU daily
Trial: 26678311
Drug: Low-dose bexarotene
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bexarotene plus PUVA
Trial: 23989505
Drug: Dental care
RxNorm normalized name: Arm And Hammer Dental Care Mint Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental care program (complimentary care before and during oncological therapy)